Mon 4/6/2020 12:15 ET
DJIA22184.411193.525.38%TELCO162.195.873.62%GOLD1690.4044.632.64%Shanghai2763.9916.580.60%
S&P 5002623.20141.925.41%BANKS297.5518.216.12%OIL26.671.676.26%BITCOIN7139.00374.805.25%
NASDAQ7759.45406.605.24%PHARM567.2313.222.33%US/EU1.080.000.00%Futures2614.62131.785.04%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Bellerophon Therapeutics - BLPH   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add BLPH
  
From: oceanviews (Rep: 447)Date: 01/30/2019 13:53
Forum: Bellerophon Therapeutics - Msg #535Thread #674060507 (Rec: 0)
WARREN, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse® Phase 2b clinical trial (iNO-PF) for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) that supports actigraphy as a clinically meaningful endpoint will be the subject of a poster presentation at the 13th Annual Pulmonary Vascular Research Institute World Congress on Pulmonary Vascular Disease, which will take place January 31 through February 3, 2019, in Barcelona, Spain.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser oceanviews: Reward | Watch | IgnoreBLPH: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add BLPH
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.